1.Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gout Therapeutics Market 

4. Market Overview
      4.1. Introduction
              4.1.1. Component Definition
              4.1.2. Industry Evolution / Developments
      4.2.  Overview
      4.3. Market Dynamics
              4.3.1. Drivers
              4.3.2. Restraints
              4.3.3. Opportunities
      4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017–2027
              4.4.1. Market Revenue Projections (US$ Mn)
      4.5. Porter’s Five Force Analysis

5. Market Outlook
      5.1.Epidemiological Overview of Gout Arthritis
      5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component 
      6.1. Introduction & Definition
      6.2. Key Findings / Developments
      6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              6.3.1. Colchicine
              6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              6.3.4. Corticosteroids
              6.3.5. Biologic Response Modifiers (Biologics)
      6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type  

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel 
      7.1. Introduction & Definition
      7.2. Key Findings / Developments
      7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              7.3.1. Hospital Pharmacy
              7.3.2. Retail Pharmacy
              7.3.3. Online Pharmacy
      7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel 

8. Global Gout Therapeutics Market Analysis and Forecast, by Region
      8.1. Key Findings
      8.2. Global Gout Therapeutics Market Value Forecast, by Region
              8.2.1. North America 
              8.2.2. Europe 
              8.2.3. Asia Pacific 
              8.2.4. Latin America 
              8.2.5. Middle East & Africa 
      8.3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. North America Gout Therapeutics Market Analysis and Forecast
      9.1. Introduction
              9.1.1. Key Findings
      9.2. North America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              9.2.1. Colchicine
              9.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              9.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              9.2.4. Corticosteroids
              9.2.5. Biologic Response Modifiers (Biologics)
      9.3. North America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              9.3.1. Hospital Pharmacy
              9.3.2. Retail Pharmacy
              9.3.3. Online Pharmacy
      9.4. North America Gout Therapeutics Market Value Forecast, by Country, 2017–2027
              9.4.1. U.S.
              9.4.2. Canada
      9.5. North America Gout Therapeutics Market Attractiveness Analysis 
              9.5.1. By Drug Type
              9.5.2. By Distribution Channel 
              9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast
      10.1. Introduction
              10.1.1. Key Findings
      10.2. Europe Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              10.2.1. Colchicine
              10.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              10.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              10.2.4. Corticosteroids
              10.2.5. Biologic Response Modifiers (Biologics)
      10.3. Europe Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              10.3.1. Hospital Pharmacy
              10.3.2. Retail Pharmacy
              10.3.3. Online Pharmacy
      10.4. Europe Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
              10.4.1. Germany
              10.4.2. U.K.
              10.4.3. France
              10.4.4. Spain
              10.4.5. Italy
              10.4.6. Rest of Europe
      10.5. Europe Gout Therapeutics Market Attractiveness Analysis 
              10.5.1. By Drug Type 
              10.5.2. By Distribution Channel 
              10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
      11.1.Introduction
              11.1.1. Key Findings
      11.2. Asia Pacific Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              11.2.1. Colchicine
              11.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              11.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              11.2.4. Corticosteroids
              11.2.5. Biologic Response Modifiers (Biologics)
      11.3. Asia Pacific Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              11.3.1. Hospital Pharmacy
              11.3.2. Retail Pharmacy
              11.3.3. Online Pharmacy
      11.4. Asia Pacific Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
              11.4.1. China
              11.4.2. Japan
              11.4.3. India
              11.4.4. Australia & New Zealand
              11.4.5. Rest of Asia Pacific
      11.5. Asia Pacific Gout Therapeutics Market Attractiveness Analysis 
              11.5.1. By Drug Type 
              11.5.2. By Distribution Channel 
              11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast
      12.1.Introduction
              12.1.1. Key Findings
      12.2. Latin America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              12.2.1. Colchicine
              12.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              12.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              12.2.4. Corticosteroids
              12.2.5. Biologic Response Modifiers (Biologics)
      12.3. Latin America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              12.3.1. Hospital Pharmacy
              12.3.2. Retail Pharmacy
              12.3.3. Online Pharmacy
      12.4. Latin America Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
              12.4.1. Brazil
              12.4.2. Mexico
              12.4.3. Rest of Latin America
      12.5. Latin America Gout Therapeutics Market Attractiveness Analysis 
              12.5.1. By Drug Type
              12.5.2. By Distribution Channel 
              12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
      13.1.Introduction
              13.1.1. Key Findings
      13.2. Middle East & Africa Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              13.2.1. Colchicine
              13.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              13.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              13.2.4. Corticosteroids
              13.2.5. Biologic Response Modifiers (Biologics)
      13.3. Middle East & Africa Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              13.3.1. Hospital Pharmacy
              13.3.2. Retail Pharmacy
              13.3.3. Online Pharmacy
      13.4. Middle East & Africa Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
              13.4.1. GCC Countries
              13.4.2. South Africa
              13.4.3. Rest of Middle East & Africa
      13.5.Market Attractiveness Analysis 
              13.5.1. By Drug Type
              13.5.2. By Distribution Channel 
              13.5.3. By Country/Sub-region

14. Competition Landscape
      14.1. Company Profiles
              14.1.1. Takeda Pharmaceutical Company Limited
                         14.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.1.2 Product Portfolio
                         14.1.1.3. SWOT Analysis 
                         14.1.1.4. Strategic Overview
                         14.1.1.5. Financial Overview
              14.1.2. Teijin Pharma Limited
                         14.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.2.2 Product Portfolio
                         14.1.2.3. SWOT Analysis 
                         14.1.2.4. Strategic Overview
              14.1.3. Novartis AG
                         14.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.3.2 Product Portfolio
                         14.1.3.3. SWOT Analysis 
                         14.1.3.4. Strategic Overview
                         14.1.3.5. Financial Overview
              14.1.4. Mylan N.V.
                         14.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.4.2 Product Portfolio
                         14.1.4.3. SWOT Analysis 
                         14.1.4.4. Strategic Overview
                         14.1.4.5. Financial Overview
              14.1.5. Horizon Pharma plc.
                         14.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.5.2 Product Portfolio
                         14.1.5.3. SWOT Analysis 
                         14.1.5.4. Strategic Overview
                         14.1.5.5. Financial Overview
              14.1.6. Teva Pharmaceutical Industries Ltd.
                         14.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.6.2 Product Portfolio
                         14.1.6.3. SWOT Analysis 
                         14.1.6.4. Strategic Overview
                         14.1.6.5. Financial Overview
              14.1.7 Hikma Pharmaceuticals PLC
                         14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.7.2 Product Portfolio
                         14.1.7.3. SWOT Analysis 
                         14.1.7.4. Strategic Overview
                         14.1.7.5. Financial Overview
              14.1.8. Iroko Pharmaceuticals, LLC 
                         14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.7.2 Product Portfolio
                         14.1.7.3. SWOT Analysis 
                         14.1.7.4. Strategic Overview
              14.1.9. MERCK & CO., Inc.
                         14.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.9.2 Product Portfolio
                         14.1.9.3. SWOT Analysis         
                         14.1.9.4. Strategic Overview
                         14.1.9.5. Financial Overview

List of Tables

Table 01: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 2: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 3: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 4: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 5: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 6: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 
2017–2027
Table 7: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 8: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 9: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 11: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 12: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 13: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 15: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 18: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 1: Global Gout Therapeutics Market Value (US$ Mn), by Drug Type 2018 (A).
Figure 2: Global Gout Therapeutics Market Share (%), by Distribution Channel, 2017 (A).
Figure 3: Opportunity Map, Drug type.
Figure 4: Opportunity Map, Distribution Channel.
Figure 5: Key Industry Developments.
Figure 6: Global Gout Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 7: Global Gout Therapeutics Market Value Share, by Drug Type (2018)
Figure 8: Global Gout Therapeutics Market Value Share, by Distribution channel (2018)
Figure 9: Global Gout Therapeutics Market Value Share, by Region (2018)
Figure 10: Global Gout Therapeutics Market Value Split, by Type (2018)
Figure 11: Global Gout Therapeutics Market Value Split, by Region (2018).
Figure 12: Global Gout Therapeutics Market Value Split, by Distribution Channel (2018)
Figure 13: Global Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 14: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Antihyperuricemic Agents (Urate-Lowering Drugs), 2017–2027
Figure 15: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2017–2027
Figure 16: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2017–2027
Figure 17: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Biologics, 2017–2027
Figure 18: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Colchicine, 2017–2027
Figure 19: Global Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 20: Global Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 21: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2017–2027
Figure 22: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2017–2027
Figure 23: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2017-2027
Figure 24: Global Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 25: Global Gout Therapeutics Market Value Share Analysis, by Region, 2018 and 2027
Figure 26: Global Gout Therapeutics Market Attractiveness Analysis, by Region, 2019?2027
Figure 27: North America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 28: North America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 29: North America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 30: North America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 31: North America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 32: North America Gout Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 33: Europe Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 34: Europe Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 35: Europe Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 36: Europe Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 37: Europe Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 38: Europe Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 39: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 40: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 41: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 42: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 43: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 44: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 45: Latin America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 46: Latin America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 47: Latin America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 48: Latin America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 49: Latin America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 50: Latin America Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 51: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 52: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 53: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 54: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 55: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 56: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 57: Takeda Breakdown of Net Sales, by Region.
Figure 58: Takeda Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2018
Figure 59: Takeda R&D Expenses (US$ Bn), 2016–2018
Figure 60: Novartis AG Breakdown of Net Sales, by Region, 2018
Figure 61: Novartis AG Breakdown of Net Sales, by Business Segment, 2018.
Figure 62: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018.
Figure 63: Novartis AG R&D Expenses (US$ Mn), 2016–2018.
Figure 64: Teva Pharmaceutical Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2018.
Figure 65: Teva Pharmaceutical R&D Expenses (US$ Bn), 2016–2018.
Figure 66: Teva Pharmaceutical Breakdown of Net Sales, By Region 2018.
Figure 67: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2018.
Figure 68: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 69: Mylan N.V. R&D Expenses (US$ Mn), 2016–2018
Figure 70: Mylan N.V.  Breakdown of Net Sales (%), by Region, 2018.
Figure 71: Breakdown of Net Sales (%), by Business Segment, 2018.
Figure 72: Horizon Pharma plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018.
Figure 73: Horizon Pharma plc R&D Expenses (US$ Mn), 2016–2018.
Figure 74: Horizon Pharma plc Breakdown of Net Sales, by Business Segment, 2018.
Figure 75: Horizon Pharma plc Breakdown of Net Sales, by Region, 2018.
Figure 76: Hikma Pharmaceuticals PLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 77: Hikma Pharmaceuticals PLC R&D Expenses (US$ Mn), 2016–2018.
Figure 78: Hikma Pharmaceuticals PLC Breakdown of Net Sales, by Business Segment, 2018
Figure 79: Hikma Pharmaceuticals PLC Breakdown of Net Sales, by Region, 2018.
Figure 80: MERCK & CO., Inc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 81: MERCK & CO., Inc PLC R&D Expenses (US$ Mn), 2016–2018.
Figure 82 MERCK & CO., Inc PLC Breakdown of Net Sales, by Business Segment, 2018
Figure 83: MERCK & CO., Inc PLC Breakdown of Net Sales, by Region, 2018.

 

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Gout Therapeutic Market

Buy Now